Part I. Policyn n Ethical Issues Associated with Pluripotent Stem Cellsn Steve Usdinn n A Researcher's Guide to Federally Funded Human Embryonic Stem Cell Research in the United Statesn Gregory J. Downingn n Intellectual Property of Human Pluripotent Stem Cellsn Mark L. Rohrbaughn n Part II. Types of Pluripotent Cellsn n Embryonal Carcinoma Cells: The Malignant Counterparts of ES and EG Cellsn Jonathan S. Draper, Harry Moore, and Peter W. Andrewsn n Human Pluripotent Cells from Bone Marrown Felipe Prosper and Catherine M. Verfaillien n Protocols for the Isolation and Maintenance of Human Embryonic Stem Cellsn Melissa K. Carpenter, Chunhui Xu, Christine A. Daigh, Jessica E. Antosiewicz, and James A. Thomsonn n Subcloning and Alternative Methods for the Derivation and Culture of Human Embryonic Stem Cellsn Michal Amit, Hanna Segev, Dorit Manor, and Joseph Itskovitz-Eldorn n Part III. Differentiationn n Differentiation of Neuroepithelia from Human Embryonic Stem Cellsn Su-Chun Zhangn n Pancreatic Differentiation of Pluripotent Stem Cellsn Nadya Lumelskyn n Human Embryonic Stem Cell-Derived Cardiomyocytes: Derivation and Characterizationn Chunhui Xu and Melissa K. Carpentern n Vascular Lineage Differentiation from Human Embryonic Stem Cellsn Sharon Gerecht Nir and Joseph Itskovitz-Eldorn n Hematopoietic Progenitors Derived from Human Embryonic Stem Cellsn Dan S. Kaufmann n Part IV. Therapeuticsn n Human Embryonic vs Adult Stem Cells for Transplantation Therapiesn Calvin B. Harley and Mahendra S. Raon n Genetic Manipulation of Human Embryonic Stem Cellsn Micha Drukker and Nissim Benvenistyn n Human Therapeutic Cloningn Jose B. Cibellin n Therapeutic Uses of Embryonic Stem Cellsn Alexander Kamb, Mani Ramaswami, and Mahendra S. Raon n Human Embryonic Stem Cells and the Food and Drug Administration: Assuring the Safety of Novel Cellular Therapiesn Donald W. Fink, Jr.n n Studies of a Human Neuron-Like Cell Line in Stroke and Spinal Cord Injury: Preclinical and Clinical Perspectivesn Paul J. Reier, John Q. Trojanowski, Virginia M-Y. Lee, and Margaret J. Velardon n Appendix I: Cell Lines and Companies Involved with Human Embryonic Stem Cell Researchn n Appendix II: Useful Websites
A discussion of all the key issues in the use of human pluripotent stem cells for treating degenerative diseases or for replacing tissues lost from trauma. On the practical side, the topics range from the problems of deriving human embryonic stem cells and driving their differentiation along specific lineages, regulating their development into mature cells, and bringing stem cell therapy to clinical trials. Regulatory issues are addressed in discussions of the ethical debate surrounding the derivation of human embryonic stem cells and the current policies governing their use in the United States and abroad, including the rules and conditions regulating federal funding and questions of intellectual property.